Journal: Carcinogenesis

Article Title: The lung-enriched p53 mutants V157F and R158L/P regulate a gain of function transcriptome in lung cancer

doi: 10.1093/carcin/bgz087

Figure Lengend Snippet: uPA protein expression is mutp53-dependent. Protein expression of uPA encoded by the RNA-seq identified gene PLAU, was assessed in p53-depleted and control conditions. (A) Western blot of A549, H2087, H441, H2110 and H2009 cells transfected with negative control or siRNA directed against p53 (25 nM). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is shown as a loading control. (B) qRT–PCR was performed to evaluate mRNA expression of PLAU after depletion of p53 by siRNA. mRNA expression values are normalized to GAPDH and siCtrl condition within each cell line. (C) Protein and conditioned media were harvested from cells after overnight incubation in reduced-serum conditions. Nitrocellulose membranes were stained with Ponceau S dye to visualize protein bands for loading control. Protein expression of pro-uPA (49 kDa) and its cleaved and activated forms B-chain (33 kDa) and A-chain (19 kDa) are shown in cell lysates and conditioned media. (D) Protein and E. mRNA expression of uPA (PLAU) following depletion of V157F mutp53 by siRNA.

Article Snippet: The following antibodies were used to detect protein expression by western blot: p53 (DO-1, sc-126; Santa Cruz), p21 (C-19, sc-397, Santa Cruz) and uPA (AF1310, R&D systems).

Techniques: Expressing, RNA Sequencing, Control, Western Blot, Transfection, Negative Control, Quantitative RT-PCR, Incubation, Staining

Journal: Future Science OA

Article Title: The P7 peptide antagonizes bFGF-induced malignant behaviors of ovarian cancer by inhibiting MEK/ERK signaling pathway

doi: 10.1080/20565623.2026.2615619

Figure Lengend Snippet: Regulation of key gene expression in OC cells by bFGF and P7 peptide. A. Bar graph of uPA mRNA expression levels; B. Bar graph of MMP2 mRNA expression levels; C. Bar graph of E-cadherin mRNA expression levels. (**: p < 0.01, ***: p < 0.001). Footnotes : bFGF: basic fibroblast growth factor, P7 peptide: P7 peptide, uPA: urokinase-type plasminogen activator, MMP2: matrix metalloproteinase-2, E-cadherin: epithelial cadherin

Article Snippet: The primary antibodies used were as follows: β-actin (81115-1-RR, Proteintech, 1:1000), E-cadherin (20874-1-AP, Proteintech, 1:1000), uPA (17968-1-AP, Proteintech, 1:1000), MMP2 (10373-2-AP, Proteintech, 1:1000), ERK1/2 (11257-1-AP, Proteintech, 1:1000), phospho-ERK1/2 (AF1015, Affinity, 1:1000), MEK1/2 (11049-1-AP, Proteintech, 1:1000), and phospho-MEK1/2 (TA8053, Abmart, 1:1000).

Techniques: Gene Expression, Expressing

Journal: Future Science OA

Article Title: The P7 peptide antagonizes bFGF-induced malignant behaviors of ovarian cancer by inhibiting MEK/ERK signaling pathway

doi: 10.1080/20565623.2026.2615619

Figure Lengend Snippet: Inhibits tumor-associated protein expression by regulating the MEK/ERK signaling pathway. A. Western blot bands of MEK, p-MEK, ERK, p-ERK, uPA, MMP2, and E-cadherin expression in each group; B. Bar graphs of total MEK protein expression (left), p-MEK expression (middle), and p-MEK/MEK ratio (right); C. Bar graphs of total ERK protein expression (left), p-ERK expression (middle), and p-ERK/ERK ratio (right); D. Bar graph of uPA protein expression; E. Bar graph of MMP2 protein expression; F. Bar graph of E-cadherin protein expression. (ns: no significance, *: p < 0.05, **: p < 0.01, ***: p < 0.001). Footnotes : bFGF: basic fibroblast growth factor, P7 peptide: P7 peptide, MEK: mitogen-activated protein kinase kinase, p-MEK: phosphorylated MEK, ERK: extracellular signal-regulated kinase, p-ERK: phosphorylated ERK, uPA: urokinase-type plasminogen activator, MMP2: matrix metalloproteinase-2, E-cadherin: epithelial cadherin, β-actin: beta-actin, KD/kDa: kilodalton

Article Snippet: The primary antibodies used were as follows: β-actin (81115-1-RR, Proteintech, 1:1000), E-cadherin (20874-1-AP, Proteintech, 1:1000), uPA (17968-1-AP, Proteintech, 1:1000), MMP2 (10373-2-AP, Proteintech, 1:1000), ERK1/2 (11257-1-AP, Proteintech, 1:1000), phospho-ERK1/2 (AF1015, Affinity, 1:1000), MEK1/2 (11049-1-AP, Proteintech, 1:1000), and phospho-MEK1/2 (TA8053, Abmart, 1:1000).

Techniques: Expressing, Western Blot